We believe that Pfizer stock (NYSE: PFE) is currently a better pick than its peer, Johnson & Johnson stock (NYSE: JNJ), given its relatively lower valuation of 3.1x trailing revenues, compared to 4.9x for J&J.
We believe that Pfizer stock (NYSE: PFE) is currently a better pick than its peer, Johnson & Johnson stock (NYSE: JNJ), given its relatively lower valuation of 3.1x trailing revenues, compared to 4.9x for J&J.
Share this Article
Recommended